LifeVantage Corporation account plan
Wellness products and programs
At a glance
LifeVantage is a Utah nutrigenomics supplement company selling through independent consultants in 17 markets, with $182.6 million of FY2026 revenue.
LifeVantage Corporation, based in Lehi, Utah, researches and sells nutrigenomic activators, dietary supplements, gut health, weight management, skin and hair care, pet and energy-drink products. It sells through a direct-selling network of independent consultants and directly to customers in 17 markets; the US is about 74% of revenue and Japan about 13%. In FY2026 (year to June 30, 2026) net revenue fell to $182.6 million from $228.5 million and net income to $5.1 million from $9.8 million. It had 223 employees at June 30, 2026 and outsources manufacturing and fulfilment. Terrence Moorehead became President and CEO in 2026, and the fiscal year moves to the calendar year from January 1, 2027.
Business units
Protandim
44.9% of FY2026 revenue ($82.0 million)The flagship line of Nrf2, NRF1 and NAD Synergizers, sold together as Protandim Tri-Synergizer. Revenue fell $13.3 million in FY2026 and was $18.0 million in Q1 fiscal 2027; a new campaign promotes Protandim Nrf2 against environmental toxins.
TrueScience
20.7% of FY2026 revenue ($37.9 million)Skin care, hair care and TrueScience Liquid Collagen. Revenue fell $10.9 million in FY2026, including about $7.3 million less Liquid Collagen in the Americas.
LifeVantage product line
17.7% of FY2026 revenue ($32.3 million)Wellness products including the MindBody GLP-1 System, Omega+, ProBio and the former PhysIQ products. MindBody GLP-1 System revenue fell to $22.5 million from $40.8 million in FY2026, driving most of the company's decline.
AXIO
$15.0 million in FY2026Nootropic AXIO Smart Energy drink mixes, extended with AXIO X and AXIO Hydrate from the LoveBiome purchase.
LoveBiome
$9.1 million in FY2026Gut-health products from the October 1, 2025 LoveBiome asset purchase, led by the patent-pending P84 System, launched in the US and Taiwan.
Petandim
$2.0 million in FY2026A Nrf2-based supplement for dogs, introduced in Mexico in March 2026.
Strategic priorities
- Reposition the brand
- The CEO wants to reposition LifeVantage as a "next generation nutraceutical company", starting with a Protandim Nrf2 campaign using before-and-after cell images.
- Digital platform and seller tools
- A new website and digital platform launch in North America in the second quarter of calendar 2027, followed by a business suite for sellers in the third quarter of 2027 with CRM, email and text outreach and social tools; AI coaching tools are 12 to 18 months out.
- Reset the economics
- Management is building a tighter organisation and reviewing all SG&A spend, with savings partly reinvested in growth.
- Focused expansion
- Growth will come from penetrating key markets and high-potential categories, using a hub-and-spoke approach around a couple of anchor markets.
- Turn the revenue trend
- The CFO expects difficult comparisons in fiscal Q1-Q2 and hopes to turn the trend in fiscal Q3-Q4; no formal guidance has been given.
Latest results
In Q1 fiscal 2027 (quarter to September 30, 2026) net revenue was $37.1 million, against $47.6 million a year earlier, on fewer active accounts and lower MindBody GLP-1 System sales, which fell $4.4 million. Gross profit percentage fell to 75.4% from 79.5%, including $1.3 million of inventory obsolescence costs. The company posted a net loss of $196 thousand against net income of $2.2 million, and adjusted EBITDA of $1.9 million. Active accounts fell 19.0% to 98,000, though subscriptions were more than 75% of revenue. Cash was $13.7 million with no debt, and no formal guidance was given.
Investments and deals
- LoveBiome acquisition
- On October 1, 2025 LifeVantage bought the critical assets of LoveBiome for a purchase price of $4.2 million, adding the P84 System and AXIO X / AXIO Hydrate drinks.
- E-commerce platform (Shopify)
- The company is replacing legacy commerce systems with a modern eCommerce platform; FY2027 capex is expected at $3 million to $3.5 million to finish it, and capex runs about $1 million a quarter.
- Data and AI foundations
- Technology spending built a data and integration foundation for future analytical and AI capabilities, alongside better consultant tools and the mobile app.
- Share buybacks
- A $60.0 million repurchase program runs through December 31, 2027, with $58.5 million still available.
Challenges and risks
- MindBody GLP-1 System decline
- Its revenue fell to $22.5 million from $40.8 million in FY2026 and inventory obsolescence costs hit gross margin.
- Shrinking consultant and customer base
- Active accounts fell to 98,000 at September 30, 2026 from 121,000, with consultants down 16.7% and customers down 20.5%.
- Consumer price pressure
- The CEO pointed to "a fair amount of price pressure that our consumers are under", with some customers pausing subscriptions.
- Intense competition
- The 10-K names intense competition in supplements, skin care, energy drinks, weight management (including GLP-1 products) and gut health.
- Market exits
- The company closed Hong Kong and Singapore in May 2026, after the Philippines in June 2025.
What leadership says
“to transform LifeVantage into a brand driven, consumer focused company that leverages digital capabilities to create an expanding community of consumers, and brand advocates”
“the overriding principle is focus. We need to become more selective about where we compete and where we invest.”
“There are a lot of supplement companies on the market, but there aren't a lot of companies like LifeVantage whose products actually help our bodies do what they're naturally built to do instead of just supplementing our diets.”
“digital is going to be a key strategy for us”
Where a supplier can help
- Seller CRM and outreach tools
- Tied to the digital platform and seller tools priority: CRM, email and text outreach, social and AI coaching components for the 2027 business suite.
- E-commerce and consumer experience
- Tied to the e-commerce platform investment: implementation, integration and site experience services for the North American launch.
- Brand and digital marketing
- Tied to the brand repositioning priority: creative, campaign and customer acquisition services for the Protandim Nrf2 campaign.
- Retention and subscription analytics
- Tied to the shrinking account base challenge: tools that reduce subscription pauses and churn among consultants and customers.
- Cost efficiency
- Tied to the reset of the economics: suppliers that lower SG&A or shipping and warehouse costs.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like LifeVantage Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- LifeVantage Corporation Annual Report on Form 10-K for the fiscal year ended June 30, 2026
- LifeVantage is a Lehi, Utah nutrigenomics company selling dietary supplements, gut health, weight management, skin and hair care, pet and energy-drink products through a direct-selling network of independent consultants in 17 markets; it reports a single operating segment.
- FY2026 (year to June 30, 2026) net revenue fell to $182.6 million from $228.5 million; operating income fell to $6.1 million from $12.2 million and net income to $5.1 million from $9.8 million. Gross margin dropped to 77.6% from 80.4%.
- The collapse of the MindBody GLP-1 System drove the decline: its revenue fell to $22.5 million from $40.8 million; the LifeVantage product line fell from $61.3 million to $32.3 million.
- Protandim remains the flagship at $82.0 million (44.9% of revenue), followed by TrueScience ($37.9 million, 20.7%) and LifeVantage ($32.3 million, 17.7%).
- The US is about 74% of revenue and Japan about 13%; the Americas region is 78.2% and Asia/Pacific & Europe 21.8%.
- Active accounts fell 21.2% to 104,000 (43,000 independent consultants, 61,000 customers). The company closed Hong Kong and Singapore in May 2026 and opened Iceland and Portugal.
- On October 1, 2025 it bought the critical assets of LoveBiome (purchase price $4.2 million), which brought the P84 gut-health system ($9.1 million revenue increase) and the AXIO X / AXIO Hydrate drinks.
- Technology spending targets a move from legacy commerce systems to a modern eCommerce platform, better consultant tools, and data foundations for future AI capabilities.
- Balance sheet: $14.9 million cash, no borrowings on a $5.0 million Bank of America line, a new $60 million buyback through December 2027, $0.185 per share dividends in FY2026, and a $75 million shelf registration.
- 223 employees (169 in the US); manufacturing, warehousing and shipping are outsourced (fulfilment by Maersk E-Commerce Logistics).
- LifeVantage Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (Q1 fiscal 2027)
- Q1 fiscal 2027 (quarter to September 30, 2026) net revenue was $37.1 million, against $47.6 million a year earlier. The drop was driven by fewer active accounts and lower MindBody GLP-1 System sales, which fell $4.4 million.
- There was a net loss of $196 thousand ($0.02 per share), against net income of $2.2 million ($0.17); operating loss was $136 thousand, against operating income of $2.3 million.
- Gross profit percentage fell to 75.4% from 79.5%, including $1.3 million of inventory obsolescence costs, $1.0 million of it for MindBody.
- Americas revenue fell 22.2% to $29.0 million (US $27.4 million). Asia/Pacific & Europe fell 21.2% to $8.2 million, with Japan down 9.5% in constant currency.
- Active accounts fell 19.0% to 98,000 (40,000 consultants, 58,000 customers).
- By product line: Protandim $18.0 million, TrueScience $7.6 million, LifeVantage $4.8 million (from $10.3 million), AXIO $2.9 million, LoveBiome $1.7 million.
- Cash was $13.7 million with no debt outstanding; capex was $1.2 million; no shares were repurchased in the quarter.
- LifeVantage (LFVN) Q4 and fiscal 2026 earnings call transcript
- This was Terrence Moorehead's first call as CEO, a few weeks after joining. He thanked Michael Beindorff, who had stepped in to lead the business during the transition.
- Moorehead's pitch: LifeVantage's products "help our bodies do what they're naturally built to do instead of just supplementing our diets", which he called "a real competitive advantage".
- He set three priorities: strengthen the LifeVantage brand, build a more relevant consumer proposition (better sales-force tools, a better consumer experience), and improve operational excellence and profitability.
- Q4 FY2026 revenue was $42.4 million, down 23.1%, on fewer orders and a lower average order size plus lower MindBody GLP-1 System sales. Adjusted EBITDA was $2.7 million.
- Subscription revenue made up more than 75% of Q4 revenue; cash was $14.9 million with no debt; there was no formal FY2027 guidance.
- The CFO expects difficult comparisons in fiscal Q1-Q2 and hopes to turn the trend in fiscal Q3-Q4. FY2027 capex is expected at $3 million to $3.5 million as the Shopify e-commerce project is finished.
- International growth will come from deeper penetration of a couple of anchor markets ("hub-and-spoke") rather than an immediate new footprint.
- LifeVantage (LFVN) Q1 fiscal 2027 earnings call transcript
- After just over 90 days in the role, CEO Terrence Moorehead set out a transformation plan to make LifeVantage a "brand driven, consumer focused company" built on digital capabilities and a community of brand advocates.
- Strategic building block 1: reposition LifeVantage as a "next generation nutraceutical company". A new Protandim Nrf2 campaign uses before/after cell images on protection against environmental toxins such as microplastics and pesticides.
- Building block 2: reimagine the business proposition. A new website and digital platform in North America in Q2 calendar 2027, then a new business suite for sellers in Q3 2027 (CRM, email/text outreach, social tools, and later AI coaching, 12 to 18 months out).
- Building block 3: expand by penetrating key markets and high-potential categories, because "the overriding principle is focus".
- The company plans to "reset the economics": a tighter organisation and an SG&A review, with savings reinvested in growth. No formal guidance.
- Fiscal year moves to the calendar year from January 1, 2027, with a 10-KT for the six months to December 31, 2026.
- Q1 revenue was $37.1 million, down 22%, and adjusted EBITDA $1.9 million. Subscriptions are more than 75% of revenue. Cash was $13.7 million with no debt; capex runs about $1 million a quarter; commissions are expected at 41% to 42% of revenue.
Questions about LifeVantage Corporation
What does LifeVantage do?
LifeVantage researches and sells nutrigenomic supplements, gut health, weight management, skin and hair care, pet and energy-drink products through independent consultants and direct customers in 17 markets.
What is LifeVantage's revenue?
FY2026 (year to June 30, 2026) net revenue was $182.6 million, down from $228.5 million. Q1 fiscal 2027 revenue was $37.1 million.
How many employees does LifeVantage have?
It had 223 employees at June 30, 2026, 169 of them in the US.
Who leads LifeVantage?
Terrence Moorehead is President and CEO, Carl A. Aure is CFO and Raymond B. Greer is Chairman.
What is LifeVantage's strategy?
It plans to reposition as a next generation nutraceutical company, launch a new digital platform and seller suite in 2027, tighten its cost base and focus on key markets and categories.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)